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S U M M A R Y
Objective: The current standard therapy for hepatitis C virus genotype 1 (HCV-1) infection is still
suboptimal. Whether adding amantadine (AMA) to pegylated interferon (PEG-IFN) plus ribavirin (RBV)
improves the virological response in treatment-naive HCV-1 patients remains unclear.
Methods: Searches of the electronic databases including Embase, Medline, Cochrane Controlled Trials
Register, and PubMed (updated to September 2011) and manual searches of the bibliographies were
carried out. A meta-analysis of randomized clinical trials (RCT) comparing triple therapy (PEG-
IFN + RBV + AMA) and double therapy (PEG-IFN + RBV) was performed.
Results: Five RCTs including 1425 patients were assessed. The meta-analysis based on the intention-to-
treat analysis indicated that the sustained virological response (SVR) rate was signiﬁcantly lower in the
triple therapy group than in the double therapy group (44.2% vs. 49.2%, risk ratio (RR) 0.90, 95%
conﬁdence interval (CI) 0.80–1.00, p = 0.05). The frequency of discontinuing therapy because of adverse
events was similar in the two groups (RR 1.26, 95% CI 0.90–1.78, p = 0.18). The sensitivity analysis
including the four studies involving Caucasian populations revealed signiﬁcantly lower SVR rates in the
triple therapy group. The other sensitivity analyses also showed similar trends, but did not reach
statistical signiﬁcance.
Conclusions: This meta-analysis suggests no beneﬁcial effect of adding AMA to PEG-IFN + RBV in
treatment-naive HCV-1 patients and even a trend towards a lower virological response rate in the triple
therapy group. This study shows that the administration of AMA should be avoided in the management
of treatment-naive HCV-1 patients.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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With an estimated prevalence of 2% worldwide, or approxi-
mately 123 million infected individuals, the public health burden
of hepatitis C virus (HCV) is substantial.1 The current standard
treatment is the combination of pegylated interferon (PEG-IFN)
and ribavirin (RBV), as recommended in the American Association
for the Study of Liver Diseases (AASLD) practical guidelines.2
Although the virological outcome has improved greatly with
interferon-based therapy in HCV genotype 2/3 infections, the
current therapy is still considered suboptimal due to a failure of
primary target sustained virological response (SVR) rate of about
50% in the ‘difﬁcult to treat’ patients (genotype 1/4).3,4 HCV
genotype 1 (HCV-1) is the most common type, accounting for
about 60% of global infections.5 Hence these studies clearly* Corresponding authors.
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http://dx.doi.org/10.1016/j.ijid.2012.06.002document the need for a more effective therapeutic regimen for
the HCV-1-infected population. Currently, two protease inhibitors
(telaprevir and boceprevir) have been approved for HCV genotype
1 and have increased the response rate.
Amantadine (AMA), an antiviral drug against the inﬂuenza A
virus, has a broad antiviral spectrum via its action on the target
protein.6 The inhibition of the HCV p7 protein (a viral ion channel) by
AMA has been observed in vitro.7 Brillanti et al. showed that the
addition of AMA to IFN + RBV combination increased SVR rates from
40% to 64% in patients with interferon-nonresponsive HCV
infections.8 In the interferon-nonresponsive patients, about 45%
were infected with an HCV genotype other than 1, and most patients
(72%) had previously received interferon alfa treatment.8 As an
initial treatment, the addition of AMA to interferon monotherapy
has been shown to increase response rates.9,10 Berg et al. random-
ized 400 treatment-naive patients to AMA or placebo, in combina-
tion with IFN + RBV.11The on-treatment viral response rates at week
24 were signiﬁcantly higher (70% vs. 59%) and SVR rates tended to be
higher (53% vs. 43%) in the AMA group. Furthermore, favorable
trends of triple therapy have been described, especially for patients
with an HCV genotype 1 infection and/or a high viral load.11,12ses. Published by Elsevier Ltd. All rights reserved.
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AMA on SVR rates in treatment-naive HCV-infected patients.13
However the study did not refer to the heterogeneity of
genotypes between groups and the different therapeutic regi-
mens, which might have affected SVR rates. The conclusions of
that meta-analysis were mainly based on regimens that
included only conventional IFN, which is not currently
recommended, and on a comparison between double therapy
and IFN monotherapy. Thus, the conclusions of the meta-
analysis cannot be used as a reference by hepatologists currently
treating treatment-naive HCV-infected patients. Since that
meta-analysis, several trials comparing the triple regimen
PEG-IFN + RBV + AMA and the double regimen PEG-IFN + RBV
have been published, especially in HCV genotype 1.
The aim of this study was to carry out a meta-analysis on the
randomized clinical trial (RCTs) comparing the efﬁcacy of triple
therapy (PEG-IFN + RBV + AMA) versus standard therapy (PEG-
IFN + RBV) in the treatment of treatment-naive HCV genotype-1
patients.
2. Methods
2.1. Literature search
A search for RCTs was conducted by two observers using
Medline (1966 to September 2011), Embase (1980 to September
2011), the Cochrane Controlled Trials Register (Cochrane Library
Issue 3, 2011), and PubMed (updated to September 2011). A full
manual search of the bibliographies of each peer-reviewed paper
selected and the abstracts from the American Digestive Disease
Week, the United European Gastroenterology Week, AASLD Annual
Meeting, and European Association for the Study of the Liver (EASL)
Annual Meeting from 2000 to 2011 was also carried out. The search
strategy was performed using medical subject headings (MeSH)
and keywords ‘hepatitis C’, ‘amantadine’, ‘interferon’, ‘ribavirin’,
‘genotype 1’. The type of article was restricted to RCT.Figure 1. Flowchart of the literatur2.2. Criteria for inclusion and exclusion of studies
Criteria for inclusion were: (1) RCT study design; (2) a
comparison of two arms: triple therapy (PEG-IFN, RBV, and
AMA) versus double therapy (PEG-IFN and RBV); (3) data provided
for treatment-naive patients with HCV genotype 1 infection; and
(4) SVR used as the primary endpoint.
Criteria for exclusion were: (1) non-RCT design; (2) data of
patients with HCV genotype 1 not detailed; (3) studies that
included patients who had received previous interferon therapy;
(4) studies in organ transplantation patients; (5) studies in patients
with HIV co-infection; and (6) publications concerning the same
study (duplicates).
2.3. Quality of methodology
The quality of included trials was scored with the Jadad
composite scale, which assesses descriptions of randomization,
double-blinding, withdrawal, and dropout.14,15 The Jadad scale
ranges from 0 to 5 points, with a low-quality study having a score
of 2 and a high-quality study having a score of 3.15 The
methodological quality assessment was performed independently
by two of the authors.
2.4. Statistical methods
The meta-analysis was performed using the meta-analysis
software, Review Manager (RevMan 5.0, Cochrane Collaboration,
Oxford, UK). We used the SVR rate to estimate the effect. We
determined the signiﬁcance of the pooled risk ratio (RR) using the
Z-test, and p < 0.05 was considered to show statistical signiﬁ-
cance.16 RRs were presented with 95% conﬁdence intervals (CI) for
each included clinical trial. Heterogeneity was assessed using the
Cochrane Chi-square test (using a 10% signiﬁcance level) and the I2
statistic (percentage of variation due to heterogeneity, with higher
values indicating a greater degree of heterogeneity). Publicatione search and selection process.
Table 1
Characteristics of the included studies
Reference Regimen Duration
(weeks)
Number of
patients
SVR rate (%) Discontinuation
for adverse events (%)
Ferenci et al. 200617 Arm 1:PEG-IFN alfa-2a 180 mg/week, RBV
1000–1200 mg/day, and AMA 200 mg/day
for 48 weeks
48 114 46.5 10.5
Arm 2: PEG-IFN alfa-2a 180 mg/week, RBV
1000–1200 mg/day, and placebo 200 mg/
day for 48 weeks
48 95 51.6 6.3
Calay et al. 200621 Arm 1: PEG-IFN alfa-2b 1.5 mg/kg/week,
RBV 800–1200 mg/day, and AMA 200 mg/
day for 48 weeks
48 128 35.4 NA
Arm 2: PEG-IFN alfa-2b 1.5 mg/kg/week
and RBV 800–1200 mg/day for 48 weeks
48 125 45.2 NA
von Wagner et al. 200820 Arm 1: PEG-IFN alfa-2a 180 mg/week, RBV
1000–1200 mg/day, and AMA from 200
mg/day to 400 mg/day within 2 weeks,
followed by AMA 400 mg/day for 46 weeks
48 352 48.6 8.5
Arm 2: PEG-IFN alfa-2a 180 mg/week and
RBV 1000–1200 mg/day for 48 weeks
48 352 52.8 4.8
Mendez-Navarro et al. 201018 Arm 1: PEG-IFN alfa-2a 180 mg/week, RBV
1000–1200 mg/day, and AMA 200 mg/day
for 48 weeks
48 61 42.6 8.2
Arm 2: PEG-IFN alfa-2a 180 mg/week and
RBV 1000–1200 mg/day for 48 weeks
48 63 39.7 9.5
van Soest et al. 201019 Arm 1: IFN alfa-2b 10 MIU/day for 6 days,
followed by 5 MIU/day for 6 days, followed
by PEG-IFN alfa-2b 1.5 mg/kg/week for 24
weeks, followed by 1.0 mg/kg/week for 26
weeks, RBV 1000–1200 mg/day, and AMA
200 mg/day for 52 weeks
52 65 35.4 13.9
Arm 2: IFN alfa-2b 10 MIU/day for 6 days, 5
MIU/day for 6 days, PEG-IFN alfa-2b
1.5 mg/kg/week for 24 weeks, followed by
1.0 mg/kg/week for 26 weeks and RBV
1000–1200 mg/day for 52 weeks
52 70 44.3 15.7
SVR, sustained virological response; PEG-IFN, pegylated interferon; RBV, ribavirin; AMA, amantadine; NA, not available.
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suggested a possible publication bias.
3. Results
3.1. Description of the selected studies
The search strategy found 40 studies. From these, we identiﬁed
ﬁve RCTs comparing triple therapy containing AMA and double
therapy for the treatment of HCV-1 infection17–21 (Figure 1). Four
studies were published as peer-reviewed articles and one study
was published as an abstract. The characteristics of the ﬁve trials
are listed in Table 1.
The meta-analysis involved 1425 patients: 720 patients were
randomized to the triple therapy group (PEG-IFN + RBV + AMA) and
705 patients to the double therapy group (PEG-IFN + RBV). Three
studies enrolled only treatment-naive genotype 1 HCV-infected
patients. The other two studies included all HCV genotypes. The
duration of treatment ranged from 48 to 52 weeks. The daily dose of
amantadine ranged from 200 mg to 400 mg. The methodological
quality scores of the trials ranged from 2 to 5 (Table 2).Table 2
Jadad score for grading the quality of the trials included in the meta-analysis
Study Randomization Blinding Withdrawal
or Dropout
Total
Ferenci et al. 200617 2 2 1 5
Calay et al. 200621 1 1 0 2
von Wagner et al. 200820 1 1 1 3
Mendez-Navarro et al. 201018 1 0 1 2
van Soest et al. 201019 2 2 1 53.2. Meta-analysis
First, we made a primary meta-analysis of trials on the SVR
rates. There was no statistical heterogeneity among the studies,
and the ﬁxed-effect model was used (Chi-square = 1.84, p = 0.76;
I2 = 0%). The meta-analysis based on the intention-to-treat analysis
indicated that the SVR rate was signiﬁcantly lower in the triple
therapy group than in the double therapy group (44.2% vs. 49.2%,
RR 0.90, 95% CI 0.80–1.00, p = 0.05) (Figure 2). The funnel plot of
trials for SVR is given in Figure 3. The slight asymmetry suggests
the possibility of publication bias.
In the meta-analysis of the rate of discontinuing therapy
because of adverse events, there was no statistical heterogeneity
among the studies (Chi-square = 3.68, p = 0.30; I2 = 18%). The
meta-analysis showed no signiﬁcant difference in the rate of
discontinuing therapy because of adverse events between the two
groups (RR 1.26, 95% CI 0.90–1.78, p = 0.18).
3.3. Sensitivity analysis
Four RCTs assessed the efﬁcacy of standard dosing regimens of
PEG-IFN + RBV combination, and one RCT was designed with the
high-dose induction therapy and decreased dose of PEG-IFN. A
sensitivity analysis was performed including only those trials
administering standard dose regimens. The analysis showed that
the SVR rate was lower in the additional AMA group, but the
difference did not reach statistical signiﬁcance (45.0% vs. 49.8%, RR
0.90, 95% CI 0.81–1.01, p = 0.09) (Table 3).
Four RCTs assessed the efﬁcacy of standard dosing regimens of
AMA combination therapy (200 mg). A sensitivity analysis was
carried out including these four studies; one study with a high
AMA dose of 400 mg was not included. The SVR rate in the triple
Figure 2. Meta-analysis on SVR rates based on intention-to-treat analysis.
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(39.9% vs. 45.6%), but there was no statistically signiﬁcant
difference between the two groups (RR 0.87, 95% CI 0.73–1.03,
p = 0.10).
Four RCTs were performed in Caucasian populations and one
RCT in a Latino population. Thus, we conducted a sensitivity
analysis including only the four studies involving Caucasian
populations. The analysis showed that the SVR rate in the triple
therapy group was signiﬁcantly lower than that in the double
therapy group (44.3% vs. 50.6%, RR 0.88, 95% CI 0.79–0.99, p = 0.03).
A ﬁnal sensitivity analysis was conducted including only the
three studies of high quality. The SVR rate in the triple therapy
group was lower than that in the double therapy group (46.6% vs.
51.5%), but the difference did not reach statistical signiﬁcance (RR
0.90, 95% CI 0.80–1.02, p = 0.10).
4. Discussion
Currently, one of the major challenges with regard to the
treatment of treatment-naive HCV patients is the need for new
approaches to increase the SVR rate in genotype 1. Chronic
hepatitis C patients with genotype 1 are considered to be ‘difﬁcult
to treat’.2 HCV genotype 1 is one of the most consistently deﬁned
virus-related factors associated with a poor response to interferon.
Many treatment-naive genotype 1 HCV patients fail to achieve SVR
with conventional combination therapy and remain at high risk for
cirrhosis, hepatocellular carcinoma, and liver-related death.22,23
Since the 1990s, many studies have explored AMA-containing
combination therapies in HCV-infected patients. Early studies
explored IFN + AMA versus IFN alone in treatment-naive
patients,10 then IFN + AMA versus IFN + RBV.24 The results were
controversial, with a few studies showing a beneﬁt with AMA. A
meta-analysis demonstrated no beneﬁt of additional AMA on SVRFigure 3. Funnel plot of trials for SVR.rates in treatment-naive HCV-infected patients,13 in which 13 of
the 17 trials compared IFN + AMA double therapy with IFN
monotherapy. Three of the other four trials compared IFN + RB-
V + AMA triple therapy with IFN + RBV double therapy. Only one
trial compared PEG-IFN + RBV + AMA triple therapy with PEG-
IFN + RBV double therapy, but this trial did not report SVR rates.
Following this, adding AMA to IFN + RBV became a point of
contention, and favorable trends with triple therapy were
described especially for patients with an HCV genotype 1 infection
and/or a high viral load.11,12 Since the introduction of PEG-IFN,
several new RCTs have been reported. Most trials have not shown
beneﬁts of adding AMA to PEG-IFN and RBV, and even lower SVR
rates in the AMA group. AMA is not recommended for the
management of HCV infection in the most recent guildelines.25,26
The current optimal therapy for a genotype 1 chronic HCV infection
is the use of boceprevir or telaprevir in combination with
peginterferon alfa and ribavirin.25,26
In our meta-analysis, we included ﬁve recent RCTs comparing
the efﬁcacy of PEG-IFN + RBV + AMA triple therapy versus PEG-
IFN + RBV double therapy for untreated patients with HCV-1
infection. The meta-analysis based on the intention-to-treat
analysis showed that the pooled SVR rate was signiﬁcantly lower
in the triple therapy group than in the standard therapy group
(44.2% vs. 49.2%). In the largest trial with 53.1% weight
contributing to this meta-analysis, a trend towards a lower
virological response rate was observed in the group of patients
receiving AMA. The lower rate of virological response in the AMA
group might be explained by the higher dropout rate in the AMA
group compared with the standard therapy group20 (32% vs. 23%).
Concerning the high dropout rate, we performed a further meta-
analysis of discontinuation for adverse events, which showed no
signiﬁcant difference between the two groups. However in the
largest trial, only adverse events unknown to PEG-IFN, RBV, and
AMA, or serious adverse events or adverse events leading to dose
modiﬁcation were reported.20 Thus, the high dropout rate in the
triple therapy group might be ascribed to the increased side effects
after adding high-dose AMA.
Racial differences in the response to antiviral therapy have been
attributed not only to diverse factors such as weight, insulin
resistance, and socio-cultural factors, but also to host factors.27,28Table 3
Sensitivity analysis on SVR rates
Number RR (95% CI) p-Value
Standard dosing regimens
of PEG-IFN + RBV
4 0.90 (0.81–1.01) 0.09
Standard AMA dose 4 0.87 (0.73–1.03) 0.10
Caucasian population 4 0.88 (0.79–0.99) 0.03
High-quality studies 3 0.90 (0.80–1.02) 0.10
SVR, sustained virological response; RR, risk ratio; CI, conﬁdence interval; PEG-IFN,
pegylated interferon; RBV, ribavirin; AMA, amantadine.
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SVR of 39–42% in the Latino population, which is lower than that in
non-Latino white patients of between 45% and 55%,29,30 but better
than that in African Americans of 28–30%.31 A sensitivity analysis
was conducted only enrolling Caucasian patients, conﬁrming the
negative effect of adding AMA in HCV genotype 1. Also, the other
sensitivity analyses of standard AMA, PEG-IFN, and RBV dose and
high-quality studies showed a trend towards poor SVR rates in the
triple therapy group.
There are some limitations in this meta-analysis. First, four of
the included RCTs did not provide detailed baseline data, in
particular the percentage of patients with advanced ﬁbrosis or
cirrhosis and the baseline viral load of HCV-1 patients. The
potential impact of these factors on the outcomes remains unclear.
Second, this study was limited by a relatively small number of
trials. Third, some studies were underpowered and this might limit
the informativeness of the study. Nevertheless, this meta-analysis
is the ﬁrst to evaluate the efﬁcacy of initial treatment with PEG-
IFN, RBV, and AMA in HCV-1 patients, and provides clinicians with
important evidence for the treatment strategy.
In conclusion, according to the evidence evaluated in our meta-
analysis, there is no beneﬁcial effect of adding AMA to PEG-
IFN + RBV in treatment-naive HCV-1 patients; in fact a trend
towards a lower virological response rate in the group of patients
receiving AMA was observed.
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